SG11201910206QA - Methods and compositions for treating inflammatory gastrointestinal disorders - Google Patents
Methods and compositions for treating inflammatory gastrointestinal disordersInfo
- Publication number
- SG11201910206QA SG11201910206QA SG11201910206QA SG11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA SG 11201910206Q A SG11201910206Q A SG 11201910206QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- eosinophilic
- road
- california
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 4
- 206010057271 eosinophilic colitis Diseases 0.000 abstract 3
- 201000001561 eosinophilic gastritis Diseases 0.000 abstract 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 2
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 abstract 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 2
- 102000051056 human SIGLEC8 Human genes 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Multimedia (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502480P | 2017-05-05 | 2017-05-05 | |
| US201762572337P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/031231 WO2018204871A1 (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910206QA true SG11201910206QA (en) | 2019-11-28 |
Family
ID=64016746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910206Q SG11201910206QA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
| SG10202112259VA SG10202112259VA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112259VA SG10202112259VA (en) | 2017-05-05 | 2018-05-04 | Methods and compositions for treating inflammatory gastrointestinal disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200270344A1 (ja) |
| EP (1) | EP3618872A4 (ja) |
| JP (2) | JP7346304B2 (ja) |
| KR (1) | KR20200015511A (ja) |
| CN (1) | CN111246880A (ja) |
| AU (1) | AU2018263937A1 (ja) |
| BR (1) | BR112019022957A2 (ja) |
| CA (1) | CA3062430A1 (ja) |
| IL (1) | IL270304B2 (ja) |
| MX (1) | MX2019013136A (ja) |
| SG (2) | SG11201910206QA (ja) |
| WO (1) | WO2018204871A1 (ja) |
| ZA (1) | ZA201907372B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3310385A4 (en) | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| KR20200016232A (ko) | 2017-05-05 | 2020-02-14 | 알라코스 인크. | 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물 |
| JP2022520105A (ja) * | 2019-02-15 | 2022-03-28 | アラコス インコーポレイテッド | マスト細胞性胃炎、マスト細胞性食道炎、マスト細胞性腸炎、マスト細胞性十二指腸炎、および／またはマスト細胞性胃腸炎を処置するための方法および組成物 |
| US20220257758A1 (en) * | 2019-08-02 | 2022-08-18 | Allakos Inc. | Methods of administering anti-siglec-8 antibodies and corticosteroids |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| WO2023141097A1 (en) * | 2022-01-24 | 2023-07-27 | Children's Hospital Medical Center | Methods of treating eosinophilic colitis |
| CN117187180B (zh) * | 2023-11-03 | 2024-01-26 | 四川大学 | 一种Th17细胞及其培养方法和应用及其诱导液 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745421B2 (en) * | 2004-05-25 | 2010-06-29 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells |
| WO2008145142A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| WO2010063785A2 (en) * | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| WO2012178188A2 (en) * | 2011-06-23 | 2012-12-27 | Children's Hospital Medical Center | Molecular diagnostic panel of eosinophilic gastrointestinal disorders |
| EP2817417B1 (en) * | 2012-02-24 | 2017-10-25 | Children's Hospital Medical Center | Esophageal microrna expression profiles in eosinophilic esophagitis |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| NZ720769A (en) * | 2013-12-09 | 2022-10-28 | Allakos Inc | Anti-siglec-8 antibodies and methods of use thereof |
| AU2015222757B2 (en) * | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| EP3310385A4 (en) * | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| KR20200016232A (ko) * | 2017-05-05 | 2020-02-14 | 알라코스 인크. | 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물 |
| JP2022520105A (ja) * | 2019-02-15 | 2022-03-28 | アラコス インコーポレイテッド | マスト細胞性胃炎、マスト細胞性食道炎、マスト細胞性腸炎、マスト細胞性十二指腸炎、および／またはマスト細胞性胃腸炎を処置するための方法および組成物 |
| KR20220018975A (ko) * | 2019-06-07 | 2022-02-15 | 에피텔리온 사이언스 바이오테크, 에스.엘. | 호산구성 위장 질환의 치료를 위한 이르소글라딘 |
| US20220257758A1 (en) * | 2019-08-02 | 2022-08-18 | Allakos Inc. | Methods of administering anti-siglec-8 antibodies and corticosteroids |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
-
2018
- 2018-05-04 EP EP18795249.4A patent/EP3618872A4/en active Pending
- 2018-05-04 CN CN201880044727.6A patent/CN111246880A/zh active Pending
- 2018-05-04 JP JP2019560756A patent/JP7346304B2/ja active Active
- 2018-05-04 SG SG11201910206Q patent/SG11201910206QA/en unknown
- 2018-05-04 SG SG10202112259VA patent/SG10202112259VA/en unknown
- 2018-05-04 CA CA3062430A patent/CA3062430A1/en active Pending
- 2018-05-04 IL IL270304A patent/IL270304B2/en unknown
- 2018-05-04 BR BR112019022957A patent/BR112019022957A2/pt unknown
- 2018-05-04 US US16/610,429 patent/US20200270344A1/en active Pending
- 2018-05-04 KR KR1020197035570A patent/KR20200015511A/ko not_active Application Discontinuation
- 2018-05-04 MX MX2019013136A patent/MX2019013136A/es unknown
- 2018-05-04 WO PCT/US2018/031231 patent/WO2018204871A1/en active Application Filing
- 2018-05-04 AU AU2018263937A patent/AU2018263937A1/en active Pending
-
2019
- 2019-11-06 ZA ZA2019/07372A patent/ZA201907372B/en unknown
-
2023
- 2023-05-15 JP JP2023080140A patent/JP2023099232A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL270304B1 (en) | 2024-03-01 |
| JP2020518645A (ja) | 2020-06-25 |
| KR20200015511A (ko) | 2020-02-12 |
| JP2023099232A (ja) | 2023-07-11 |
| IL270304A (en) | 2019-12-31 |
| US20200270344A1 (en) | 2020-08-27 |
| ZA201907372B (en) | 2024-04-24 |
| EP3618872A1 (en) | 2020-03-11 |
| JP7346304B2 (ja) | 2023-09-19 |
| WO2018204871A1 (en) | 2018-11-08 |
| CN111246880A (zh) | 2020-06-05 |
| IL270304B2 (en) | 2024-07-01 |
| BR112019022957A2 (pt) | 2020-05-19 |
| CA3062430A1 (en) | 2018-11-08 |
| EP3618872A4 (en) | 2021-06-30 |
| SG10202112259VA (en) | 2021-12-30 |
| AU2018263937A1 (en) | 2019-12-05 |
| MX2019013136A (es) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201906238TA (en) | Split sector level sweep using beamforming refinement frames | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |